Home/Pipeline/ENL‑102

ENL‑102

Non‑alcoholic fatty liver disease

PreclinicalActive

Key Facts

Indication
Non‑alcoholic fatty liver disease
Phase
Preclinical
Status
Active
Company

About Enlila

Biotech startup translating Harvard metabolic research into therapies to extend health span and treat age‑related diseases.

View full company profile